30-day average of 15 articles ยท scale โ100 to +100
Across 15 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of Amgen news is Somewhat Bullish (+44)
on a scale from โ100 to +100.
That is up 10 points from the previous 30 days (+34).
๐ Amgen reported $38.9B revenue and $9.4B net income for fiscal 2026.
๐ฆ Company maintained 6.3x debt-to-equity ratio with $8.1B free cash flow.
Slightly Bullish +25
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
AI-generated analysis
Key insights
๐ Amgen reported revenue of approximately $38.9 billion and net income of nearly $9.4 billion for the 12 months ended Sept. 30, 2026.
๐ฆ The company maintained a debt-to-equity ratio of roughly 6.3x and generated free cash flow of about $8.1 billion as of Dec. 31, 2025.
๐ Amgen is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion despite being a mature business.
๐ค Amgen reached a deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for tariff exemptions for three years.
๐ญ Nearly 77% of Amgen's revenues in 2025 came from sales to three large distributors: McKesson, Cencora, and Cardinal Health.
๐ The company possesses six drug franchises that generate $1 billion-plus in annual revenue, providing a stable cash flow base.
๐ Amgen is characterized as an affordable option for value-conscious investors based on its significantly lower Forward P/E and P/S ratios.
๐ Bullish signals
๐Amgen maintains a diversified portfolio across oncology and rare diseases, providing a steady business model with six drug franchises generating over $1 billion in annual revenue each.
๐The company is projected to achieve roughly 3% revenue growth in fiscal 2026, reaching around $37.8 billion, supported by its massive scale and cash generation capabilities.
๐คAmgen secured a strategic deal with the U.S. government to lower prices on key drugs Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
๐ Risk factors
๐The company faces substantial competition from biosimilars and generics, which can erode the market share of its older products.
๐Operational risks include a heavy reliance on specific manufacturing facilities in Puerto Rico and California.
Article
The article compares Amgen (AMGN) and Vertex Pharmaceuticals (VRTX), highlighting Amgen's diversified business model across oncology and rare diseases versus Vertex's high-growth specialization in genetic conditions. It notes that Amgen sells primarily through three large distributors, which accounted for nearly 77% of its revenues in 2025, adding a layer of customer concentration risk to the business.
Financial data reveals that in the 12 months ended Sept. 30, 2026, Amgen generated revenue of approximately $38.9 billion and net income of nearly $9.4 billion. The company maintains a debt-to-equity ratio of roughly 6.3x and produced free cash flow of about $8.1 billion for the fiscal year ended Dec. 31, 2025.
Amgen faces competition from biosimilars and pricing pressure but is positioned to achieve roughly 3% revenue growth in 2026, reaching around $37.8 billion. The company recently reached a deal with the U.S. government to lower prices on key drugs like Aimovig and Amjevita in exchange for exemption from pharmaceutical tariffs for three years.
Analysts view Amgen as an affordable option for value-conscious investors due to its lower Forward P/E and P/S ratios compared to Vertex. While not a fast-growing company by sales, its scale allows it to pursue future growth through acquisitions, supported by six drug franchises generating over $1 billion in annual revenue each.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Amgen stock is currently trading at a discount, supported by a fundamental profile that includes reasonable growth potential, sustained cash flow and margins, and a low debt-to-market-cap ratio. The investment thesis relies heavily on the commercial success of its growth portfolio, specifically highlighting Repatha, Evenity, and Tezspire, as well as the maturation of late-stage pipeline assets like the obesity drug MariTide intended to replace revenue lost from legacy products facing loss of exclusivity. However, the prevailing market sentiment remains bearish, with the core debate centering on whether growth from new products can outpace confirmed revenue erosion from biosimilar competition against legacy blockbusters such as Prolia and Xgeva.
The challenges facing the company include structural headwinds that are largely negating strong volume growth in new products, persistent net price erosion across the portfolio, and a newly emerged regulatory risk. Consequently, many analysts view the narrative as shifting from a pure growth story to a turnaround story characterized by low visibility into future outcomes. While individual stock performance is considered unpredictable, the article suggests that a diversified portfolio of high-quality stocks trading below their one-year highs with P/E ratios below S&P 500 median and P/S ratios below historical averages could offer better risk-adjusted returns.
As an illustration of the potential of such a strategy, a portfolio constructed on December 31, 2016, with stocks fulfilling these criteria achieved average six-month and 12-month forward returns of 12.7% and 25.8%, respectively, with a win rate exceeding 70%. The broader text suggests that instead of betting on the individual trajectory of Amgen alone, investors might consider approaches like the Trefis High Quality Portfolio, which invests in 30 diverse stocks to deliver stronger upside with reduced volatility. The article also references other market-moving themes and stock-specific analyses, including mid-cap and large-cap stocks trading at 52-week highs and various S&P 500 movers, indicating a focus on finding bargains within specific sectors like technology and healthcare.
๐ Amgen trades at a discount with reasonable growth and cash flow.
๐ฐ Investors rely on MariTide maturation to offset legacy revenue erosion.
๐ The thesis shifted from growth to an uncertain turnaround story.
๐ Diversified portfolios reduce risk and have delivered strong forward returns.
๐ Amgen (AMGN) stock is currently trading at a discount with reasonable growth, cash flow, and margins.
๐ฐ Investors are betting on the commercial success of the growth portfolio including Repatha, Evenity, and Tezspire.
๐ The long-term strategy relies on MariTide maturation to replace revenue lost from legacy products losing exclusivity.
โ ๏ธ The main investment debate centers on whether new product growth can outpace accelerated revenue erosion from biosimilar competition.
๐ Legacy blockbusters like Prolia and Xgeva are facing significant structural headwinds and price erosion.
๐ป Current market sentiment is predominantly bearish due to persistent net price erosion and low visibility.
๐ The investment thesis has shifted from a growth story to a turnaround story with uncertain outcomes.
๐ผ Readers are encouraged to evaluate the fundamentals further via provided AMGN investment highlights analysis.
๐ Alternative mid-to-large cap stocks are noted as trading below 1-year highs with P/E and P/S below historical averages.
๐ A portfolio strategy built on similar criteria has delivered 25.8% 12-month forward returns with a win rate above 70%.
๐ Individual stocks like AMGN may be unpredictable, suggesting diversification through portfolios reduces downside risk.
๐ The Trefis High Quality Portfolio invests in 30 diverse stocks to deliver higher upside with reduced volatility.
โ ๏ธ Several other articles are mentioned, including topics on Akamai, McKesson, Netflix, Chevron, Ralph Lauren, and Broadcom.
Bullish Signals
Amgen trades at a discount with low debt and strong cash flow.
Long-term thesis depends on success of growth portfolio including Repatha.
MariTide aims to replace revenue lost from products facing exclusivity loss.
Alternative stocks delivered 25.8% average returns with win rate above 70%.
High Quality Portfolio offers stronger upside and reduced volatility versus indices.
Risk Factors
Bearish sentiment questions product growth offsets for headwinds.
Blockbuster revenues decline faster due to biosimilar competition.
Persistent net price erosion compounds patent expiration risks.
Thesis shifted from growth to turnaround with low profit visibility.
Regulatory risks threaten commercial success of growth portfolio.
Bullish Signals
Amgen is trading at a discount with reasonable growth prospects, sustained cash flow, margins, and a low debt-to-market-cap ratio.
The long-term investment thesis relies on the commercial success of Amgen's growth portfolio including Repatha, Evenity, and Tezspire.
The maturation of its late-stage pipeline, particularly the obesity drug MariTide, aims to replace revenue lost from legacy products facing loss of exclusivity.
Alternative stocks following a similar investment strategy delivered an average 12-month forward return of 25.8% with a win rate above 70%.
The Trefis High Quality Portfolio invests in diverse stocks that have collectively delivered stronger upside and reduced volatility compared to broader indices.
Risk Factors
The prevailing market sentiment toward Amgen is explicitly bearish, with investors questioning whether new product growth can offset structural headwinds.
Legacy blockbuster revenue centers are facing an accelerated decline due to biosimilar competition, specifically affecting drugs like Prolia and Xgeva.
The company's portfolio is experiencing persistent net price erosion, which further compounds the revenue erosion risks from patent expirations.
The investment thesis has shifted from a growth story to a turnaround story with low visibility regarding future profitability or market share retention.
New regulatory risk has emerged as a critical factor that could impact the commercial success of Amgen's growth portfolio and pipeline maturation.
Amgen Canada announced on April 7, 2026, that the governments of Ontario and Quebec have expanded public reimbursement for Repatha (evolocumab) to include eligible patients following an acute coronary syndrome (ACS). In Ontario, coverage under the Ontario Drug Benefit program now includes patients within 52 weeks of an ACS event who fail to meet cholesterol targets despite standard lipid-lowering therapies. Quebec had already granted public listing for this indication on February 4, 2026, extending coverage to patients up to 24 months post-ACS with similar efficacy criteria. These expansions aim to address the high risk of recurrent cardiovascular events in the years following a heart attack or acute cardiac event, particularly among patients whose LDL cholesterol levels remain above the recommended threshold of 1.8 mmol/L despite statin therapy.
Data highlights that approximately 42% of Canadian patients with a history of ACS remain above guideline-recommended LDL-C targets, and nearly half of those exceeding 1.8 mmol/L experience another cardiovascular event within 3.4 years, with one in four suffering cardiovascular death. Repatha, a PCSK9 inhibitor approved in over 70 countries for more than 8.5 million patients globally, works by increasing the liver's ability to remove LDL cholesterol from the bloodstream. The expanded coverage is supported by medical experts and Amgen Canada executives who emphasize the critical need for early access to effective lipid-lowering therapies after an acute cardiac event to reduce long-term risk.
๐ Ontario and Quebec expanded public Repatha coverage for eligible ACS patients post-heart attack.
๐ Repatha inhibits PCSK9 to boost liver removal of bad cholesterol via autoinjector.
๐คฐ Drug safety data is limited for pregnancy and not established for children under 10.
๐๏ธ Amgen Canada announced that Ontario and Quebec have expanded public reimbursement for Repatha (evolocumab) to cover eligible recent acute coronary syndrome (ACS) patients.
๐ In Ontario, the Ontario Drug Benefit (ODB) program now covers patients within 52 weeks of an ACS who fail to meet cholesterol targets on standard therapy.
๐ก๏ธ Quebec expanded coverage earlier, listing Repatha for ACS on February 4, covering patients up to 24 months post-event who do not meet lipid targets despite statin treatment.
โ๏ธ Dr. Jean C. Grรฉgoire from the Montreal Heart Institute praised Quebec's move as pioneering and encouraged other provinces to follow suit in managing cardiovascular risk.
๐ผ Daniel Jun Martinez of Amgen Canada stated that public funding is crucial for accessing effective lipid-lowering therapy early after an acute cardiac event.
โ ๏ธ Statistics show that 42% of Ontario patients with a history of ACS remain above recommended LDL-C thresholds despite treatment, increasing future event risk.
๐ Patients with elevated LDL-C above 1.8 mmol/L after an ACS face nearly a 50% chance of another cardiovascular event within 3.4 years and a significant mortality risk.
๐จโโ๏ธ Dr. Shaun Goodman from St. Michael's Hospital emphasized that ongoing lipid-lowering treatment is critical for heart health support after hospital discharge.
โค๏ธ Over 60,000 Canadians experience a first heart attack annually, and Repatha addresses risks associated with coronary artery disease where plaque buildup reduces blood flow.
๐ฉบ Dr. Jeffrey Habert noted that expanding access to additional therapies allows clinicians to act sooner to prevent potentially fatal future cardiovascular events.
๐ Repatha works by inhibiting PCSK9, preventing the degradation of LDL receptors and increasing the liver's ability to remove "bad cholesterol" from the bloodstream.
๐ Globally, Repatha is approved in over 70 countries, has 8.5 million patients, and has been studied in more than 50 clinical trials involving over 57,000 participants.
๐ The medication is administered via a single-use prefilled SureClick autoinjector for ease of use.
โ ๏ธ Contraindications include hypersensitivity to Repatha or any ingredient in the formulation.
โ ๏ธ Hypersensitivity reactions such as rash, urticaria, and angioedema have been reported with use.
๐คฐ Data on efficacy and safety in pregnant or nursing women is very limited, and the drug should be discontinued if a patient becomes pregnant.
๐ถ Efficacy and safety have not been established in pediatric patients under 10 years of age for certain genetic conditions like HeFH and HoFH.
๐ Full reimbursement criteria and details are available through the respective provincial formulary websites (ODB for Ontario and RAMQ for Quebec).
Bullish Signals
Ontario expanded reimbursement for Repatha within 52 weeks of ACS.
Quebec became the first province to list Repatha on February 4.
Repatha addresses unmet needs as 42% of patients exceed LDL thresholds.
Globally, Repatha treats over 8.5M patients in more than 70 countries.
Risk Factors
Reported hypersensitivity reactions may require discontinuation.
Limited safety data exist for pregnant or nursing women.
Infants exposed via breast milk face unknown risks.
Efficacy unestablished in pediatric patients under 10 years.
42% of Canadian ACS patients remain above LDL-C targets.
Bullish Signals
Amgen Canada announced that the Governments of Ontario and Quebec have expanded public reimbursement for Repatha(R) (evolocumab injection) for eligible patients following an acute coronary syndrome (ACS).
In Ontario, updated coverage through the Ontario Drug Benefit (ODB) program now includes eligible patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard lipid-lowering therapies.
Quebec listed Repatha for public coverage on February 4, becoming the first province to do so, with eligibility extending up to 24 months following an ACS.
This expansion addresses a significant unmet need, as 42% of Canadian patients with a history of ACS remain above LDL-C guideline thresholds despite treatment.
Globally, Repatha has established a strong presence with over 8.5M patients and approval in more than 70 countries.
The drug is administered via a single-use prefilled SureClick(R) autoinjector, supporting patient convenience and adherence.
Risk Factors
Repatha has reported hypersensitivity reactions including rash, urticaria, and angioedema, requiring discontinuation if serious allergic symptoms occur.
There is very limited data on the safety of Repatha in pregnant and nursing women, with no studies conducted specifically for these populations.
The effects on breastfed infants cannot be excluded due to a lack of information regarding evolocumab presence in human milk.
Efficacy and safety data are limited for HoFH patients aged 10-11 years, and the drug's efficacy has not been established in pediatric patients under 10 years old.
Despite public funding expansion, 42% of Canadian ACS patients remain above recommended LDL-C thresholds, suggesting potential gaps in current standard-of-care adherence.
Amgen Canada announced on April 7, 2026, that the governments of Ontario and Quebec have expanded public reimbursement coverage for Repatha (evolocumab injection) to include eligible patients following an acute coronary syndrome. In Ontario, through the Ontario Drug Benefit program, coverage now applies to patients within 52 weeks of an ACS event who are not achieving cholesterol targets despite standard lipid-lowering therapies. Previously covered by the drug but now expanded in eligibility, this update aligns with Canadian cardiovascular risk management strategies for recent cardiac events. Quebec had already been a pioneer in this area, listing Repatha for ACS on February 4 as the first province to do so; its updated criteria now cover eligible patients up to 24 months following an event, also focusing on those failing to meet targets on standard therapy.
The significance of these expansions is driven by high-risk data showing that patients remaining above LDL-C thresholds after an initial event face a substantially elevated risk of recurrent cardiovascular events or death. Statistics cited indicate that 42% of Ontario patients with ACS history remain above recommended LDL-C levels despite treatment, and nearly half of those above the 1.8 mmol/L threshold will experience another event within 3.4 years. Repatha, a monoclonal antibody inhibitor of PCSK9, is approved globally for over 70 countries and has treated 8.5 million patients in clinical trials involving more than 57,000 individuals. The drug works by increasing the liver's ability to remove LDL cholesterol from the bloodstream, serving as an adjunct to diet and standard therapy for reducing risks of heart attack, stroke, and coronary revascularization. While full reimbursement criteria remain available through provincial formularies like ODB and RAMQ, medical experts emphasize that timely access to these therapies is critical during the high-risk years following a cardiac event.
๐ Ontario and Quebec expanded public coverage for Repatha to treat eligible ACS patients.
๐ Expansion targets 42% of Ontario patients with lingering high LDL-C risks.
๐ Therapy inhibits PCSK9 to lower bad cholesterol and prevent recurrent events.
โ Contraindications include hypersensitivity, limited pregnancy safety data, and exclusion for under-10s.
- ๐๏ธ Amgen Canada announced that Ontario and Quebec have expanded public coverage for Repatha (evolocumab) to treat eligible patients following an acute coronary syndrome (ACS).
- ๐ฆ In Ontario, reimbursement under the Ontario Drug Benefit program applies to patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard therapy.
- ๐ Quebec became the first province in Canada to publicly list Repatha for ACS coverage in February, extending eligibility up to 24 months post-event for those failing lipid targets on standard care.
- ๐ Statistics show that 42% of Ontario patients with a history of ACS remain above recommended LDL-C thresholds, while nearly half of Canadian patients at this elevated risk face another cardiovascular event within 3.4 years.
- ๐จโโ๏ธ Medical experts highlighted that lowering LDL cholesterol is critically important after leaving the hospital to support heart health and reduce the risk of recurrent events.
- ๐ Repatha works by inhibiting PCSK9, a mechanism that increases the liver's ability to remove "bad cholesterol" from the bloodstream to lower cardiovascular risk.
- ๐ Globally, Repatha is approved in over 70 countries with a patient base of 8.5 million and has been studied in more than 50 clinical trials involving over 57,000 patients.
- โ ๏ธ The product carries contraindications for hypersensitivity to evolocumab or its ingredients, requiring discontinuation if signs of serious allergic reactions occur.
- ๐คฐ There is limited data regarding the use of Repatha in pregnant women and nursing women, and it should be discontinued if a patient becomes pregnant.
- ๐ง Efficacy and safety have not been established for pediatric patients under 10 years of age with specific types of hyperlipidemia such as HoFH.
- ๐ฅ Clinical guidelines recommend additional lipid-lowering treatment when LDL-C remains above 1.8 mmol/L following an ACS to mitigate future event risks.
- ๐ฐ Public funding expansion aims to help more patients access appropriate therapy early after a cardiac event, which is critical for reducing future risk.
- ๐ Full reimbursement criteria and details are available through the Ontario Drug Benefit program or the Rรฉgie de l'assurance maladie du Quรฉbec (RAMQ) formulary.
- ๐ฆ The expansion reflects a growing focus on managing cardiovascular risk in the years immediately following an initial acute coronary syndrome event.
Bullish Signals
Amgen Canada secured expanded public reimbursement for Repatha in Ontario and Quebec.
Quebec became the first province to list Repatha on February 4.
Ontario now covers eligible patients up to 52 weeks after an ACS event.
Repatha targets the 42% of Ontario patients with high LDL-C post-ACS.
Global approval in over 70 countries is based on 57,000 patient studies.
Risk Factors
Not indicated for pregnant or nursing women due to limited data.
Efficacy and safety unestablished in pediatric patients under 10 years.
Reported hypersensitivity reactions include rash, urticaria, and angioedema.
Requires discontinuation in severe renal or hepatic impairment cases.
Bullish Signals
Amgen Canada announced that the Governments of Ontario and Quebec have expanded public reimbursement for Repatha, marking a significant increase in patient access to this life-saving therapy.
In Quebec, Repatha was publicly listed on February 4 as the first province to do so, covering eligible patients up to 24 months following an acute coronary syndrome event.
Ontario's updated coverage through the Ontario Drug Benefit program now includes eligible patients within 52 weeks of an ACS who are not meeting cholesterol targets despite standard therapies.
This expansion is critical given that in Ontario, 42 per cent of patients with a history of an ACS remain above Canadian lipid guideline-recommended LDL-C thresholds despite treatment.
Global data supports the efficacy of Repatha, showing it has 8.5 million patients worldwide and is approved in over 70 countries based on studies involving over 57,000 patients.
Repatha's mechanism of action increases the liver's ability to remove LDL-C from the bloodstream, directly addressing the high risk of recurrent cardiovascular events following an ACS.
Risk Factors
Repatha is not indicated for use in pregnant or nursing women, and data on its safety in these populations is very limited.
Efficacy and safety have not been established in pediatric patients under 10 years of age with hyperlipidemia, and data is limited for those aged 10-11 years with HoFH.
Hypersensitivity reactions such as rash, urticaria, and angioedema have been reported in clinical use.
The drug requires discontinuation in patients with severe renal or hepatic impairment, which limits its applicability to a smaller subset of the patient population.
Amgen has announced positive top-line results from a Phase III clinical trial evaluating subcutaneous Tepezza (teprotumumab-trbw), an intravenous therapy approved for treating moderate-to-severe active thyroid eye disease (TED). The study utilized an on-body injector (OBI) to deliver the drug subcutaneously, demonstrating efficacy comparable to the existing intravenous formulation. The trial met its primary endpoint by achieving a statistically significant 77% proptosis response rate at 24 weeks, with an average reduction in proptosis of 3.17mm at the same time point.
Additional secondary endpoints were also successfully met, including improvements in overall responder rates, clinical activity scores, diplopia changes, and quality of life metrics related to Graves' Ophthalmopathy. Safety profiles for the subcutaneous formulation matched those of the intravenous version, with mild-to-moderate injection site reactions being manageable without requiring treatment interruption. Common adverse events included diarrhea, nausea, and muscle spasms. The trial enrolled patients diagnosed within the previous 15 months with significant proptosis who received dosing every two weeks for a total of 12 administrations.
Jay Bradner, Amgen's executive vice-president for research and development, stated that these results support Tepezza as a best-in-class option, offering a more convenient delivery method to potentially reach a broader patient population. The findings represent a significant step forward for patients with this rare autoimmune condition by simplifying the administration process while maintaining established clinical benefits. This development is distinct from Amgen's other concurrent research, such as the ASCEND trial for atopic dermatitis announced in September 2025, and focuses specifically on optimizing the delivery mechanism for its established TED treatment.
โ Subcutaneous Tepezza matched IV efficacy with a 77% proptosis response rate at 24 weeks.
๐ Secondary endpoints met, including 3.17mm average proptosis reduction and improved quality of life.
๐ New on-body injector allows convenient bi-weekly dosing for up to six months without infusion.
๐ฅ Amgen reported positive top-line results for its Phase III trial of subcutaneous Tepezza in adults with moderate-to-severe active thyroid eye disease (TED).
๐ The new subcutaneous formulation, delivered via an on-body injector (OBI), achieved efficacy comparable to the currently approved intravenous (IV) version.
๐ The trial met its primary endpoint, showing a statistically significant 77% proptosis response rate at 24 weeks compared to placebo.
๐ Secondary endpoints were also met, including an average proptosis reduction of 3.17mm and improvements in clinical activity scores and quality of life measures.
โ ๏ธ While visual function showed a numerical trend favoring the drug, it did not reach statistical significance in this study.
๐ก๏ธ Safety outcomes for the subcutaneous formulation matched those of the IV version, with mild-to-moderate injection site reactions being manageable.
๐คข The most common adverse events observed included diarrhoea, ear discomfort, muscle spasms, nausea, tinnitus, and weight decrease.
๐๏ธ Tepezza (teprotumumab-trbw) treats TED, a rare autoimmune disease causing proptosis, double vision, and other eye complications.
๐ The trial enrolled participants with moderate-to-severe TED within the previous 15 months who had at least 3mm of proptosis.
๐ Dosing involved administration every two weeks for 12 total doses using the on-body injector system.
๐ฃ๏ธ Jay Bradner, Amgen's executive vice-president of research and development, stated the results extend the best-in-class efficacy of Tepezza with a more convenient delivery method.
๐ The subcutaneous option aims to potentially reach more patients by improving convenience compared to intravenous infusion.
๐ This news was updated on April 7, 2026, following initial Phase III findings from the ASCEND trial in September 2025.
๐ข Tepezza is developed by Amgen and Kyowa Kirin, focusing on rebalancing T-cells to treat autoimmune conditions.
Bullish Signals
Amgen reported positive Tepezza Phase III results for thyroid eye disease.
Subcutaneous formulation matches IV efficacy via convenient on-body injector.
Trial achieved 77% proptosis response rate at week 24.
Proptosis reduced average by 3.17mm with matched safety profile.
ASCEND trial findings show pipeline innovation for rocatinlimab in 2025.
Risk Factors
Visual function improvements showed numerical trends only, lacking statistical significance.
Strict inclusion criteria may limit results' generalizability to broader patient groups.
Trial restricted to moderate-to-severe TED patients within 15 months and 3mm proptosis.
Subcutaneous Tepezza safety outcomes lacked significant impact on visual function metrics.
Patient selection exclusions narrow applicability beyond the specific trial population.
Bullish Signals
Amgen reported positive top line results from its Phase III subcutaneous Tepezza trial for adults with moderate-to-severe active thyroid eye disease (TED).
The new subcutaneous formulation achieved efficacy comparable to the already approved intravenous Tepezza, delivering IV-level performance via a convenient on-body injector.
The trial met its primary endpoint with a statistically significant 77% proptosis response rate at 24 weeks.
Key secondary endpoints were also met, including an average reduction in proptosis of 3.17mm at week 24 and significant improvements in clinical activity score and quality of life.
Safety outcomes for the subcutaneous version matched the IV formulation, with mild-to-moderate injection site reactions that did not require interruption or stopping of treatment.
Executive Vice-President Jay Bradner noted these results extend and support the best-in-class efficacy of Tepezza, potentially reaching more patients through a more convenient delivery option.
In September 2025, Amgen also announced initial top line findings from the Phase III ASCEND trial for rocatinlimab in atopic dermatitis, showing ongoing innovation pipeline activity.
Risk Factors
Safety outcomes for subcutaneous Tepezza were limited to a numerical trend without statistical significance in visual function improvements, despite positive findings in other secondary endpoints.
The trial inclusion criteria restricted participation to patients with a diagnosis of moderate-to-severe TED within the previous 15 months and proptosis of 3mm or greater from baseline, potentially limiting generalizability to broader patient populations.
Amgen announced positive topline results from a Phase 3 clinical trial for its drug TEPEZZA (teprotumumab-trbw) administered via subcutaneous injection using an on-body injector (OBI). The trial evaluated the efficacy and safety of this new delivery method in adults with moderate-to-severe active Thyroid Eye Disease (TED), a serious autoimmune condition that can cause eye bulging, double vision, and pain.
The study met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate over 24 weeks for the TEPEZZA OBI group compared to just 19.6% for the placebo group. This performance is comparable to the existing intravenous (IV) version of TEPEZZA, which has treated more than 25,000 patients worldwide. Secondary endpoints also showed clinically meaningful improvements in overall response rates, reduction in clinical activity scores, and improvements in diplopia and quality of life metrics.
Regarding safety, the adverse event profile was consistent with known risks associated with TEPEZZA IV, including muscle spasms, tinnitus, weight loss, and nausea. Mild-to-moderate injection site reactions were observed but did not require treatment interruption. The trial design involved participants receiving injections every two weeks for a total of 12 doses if they received the drug. Additionally, Amgen noted the completion of a separate Phase 3b/4 trial to satisfy FDA post-marketing requirements for the IV formulation, which assessed different treatment durations and retreatment needs. Dr. Jay Bradner of Amgen's R&D department stated that this subcutaneous option aims to provide a more convenient and accessible delivery method while maintaining best-in-class efficacy for this rare disease.
๐ Amgen's Phase 3 trial confirmed subcutaneous TEPEZZA efficacy with 77% response vs 19.6% placebo.
๐ฅ Treatment achieved greater than 3 mm eye bulging reduction, meeting primary clinical endpoints.
๐ Convenient bi-weekly shots replace IV infusions, expanding access with consistent safety profiles.
Amgen announced positive topline results from a Phase 3 trial for subcutaneous TEPEZZA in treating moderate-to-severe active Thyroid Eye Disease (TED).
The study demonstrated that the on-body injector version of TEPEZZA achieved comparable efficacy to the existing intravenous formulation.
77% of patients receiving subcutaneous TEPEZZA experienced a highly statistically significant proptosis response compared to 19.6% with placebo over 24 weeks.
The trial met its primary endpoint, showing a clinically meaningful reduction in eye bulging of greater than 3 mm.
Additional secondary endpoints showed improvements including overall responder rates and reductions in double vision and clinical activity scores.
Safety results were consistent with the known profile of intravenous TEPEZZA, with mild-to-moderate injection site reactions as the most common adverse events.
Subcutaneous administration allows for more convenient bi-weekly injections over 12 doses compared to the current IV infusion requirement.
Jay Bradner of Amgen's R&D noted that this delivery method potentially expands access to patients while maintaining best-in-class efficacy.
Dr. Madhura Tamhankar from the University of Pennsylvania highlighted that subcutaneous options make the treatment more accessible for diverse patient needs.
The study included participants with baseline hearing impairment, broadening eligibility for a rare autoimmune condition often linked to Graves' disease.
Full results from this Phase 3 trial will be presented at an upcoming medical congress.
A separate Phase 3b/4 trial to fulfill FDA post-marketing requirements for the IV formulation has also been completed and showed a consistent risk profile.
Bullish Signals
Amgen positive Phase 3 top results for subcutaneous TEPEZZA.
77% proptosis response rate vs 19.6% placebo at 24 weeks.
Subcutaneous form offers IV efficacy with convenient on-body injection.
Strong safety baseline from prior IV treatment up to 25,000 patients.
Mild-to-moderate injection site reactions did not require treatment interruption.
Risk Factors
Visual function benefit at Week 24 was not statistically significant.
Tinnitus and ear discomfort risks limit eligibility in hearing impaired patients.
Injection site reactions may affect tolerance and compliance for subcutaneous use.
Extended infusion safety profiles remain unapproved and under investigation.
Bullish Signals
Amgen announced positive topline results for Phase 3 trials of subcutaneous TEPEZZA in adults with moderate-to-severe active Thyroid Eye Disease (TED).
77% of patients achieved a highly statistically significant proptosis response rate during the 24-week placebo-controlled period, compared to only 19.6% for placebo.
The new subcutaneous formulation delivers IV-level efficacy while offering a more convenient on-body injector administration method that could reach more patients.
TEPEZZA OBI showed clinically meaningful improvements across multiple secondary endpoints, including overall responder rates and reduction in double vision (diplopia).
The study included up to 25,000 patients worldwide previously treated with IV TEPEZZA, establishing a strong safety baseline for the new subcutaneous option.
Safety results were generally consistent with the known profile of TEPEZZA IV, with mild-to-moderate injection site reactions not resulting in treatment interruptions or discontinuations.
Risk Factors
While results were positive, the numerical trend favoring TEPEZZA OBI in the visual functioning subscale was not statistically significant at Week 24, leaving some uncertainty about the subcutaneous formulation's impact on functional vision quality.
The Phase 3 trial included participants with baseline hearing impairment, and common adverse events included tinnitus and ear discomfort, indicating potential auditory toxicity risks that may limit patient eligibility or cause discontinuation in vulnerable populations.
Mild-to-moderate injection site reactions were observed with subcutaneous administration in some patients, suggesting a localized safety profile that differs from the established intravenous formulation and could affect patient tolerance or compliance.
The post-marketing requirement study for TEPEZZA IV was conducted to specifically evaluate long-term safety and tolerability across different infusion durations (four, eight, and 16 infusions), implying that extended use profiles are not yet fully characterized or approved.
The provided text does not contain substantive news about Amgen Inc. ($AMGN) or the acquisition of its shares by Thurston Springer Miller Herd & Titak Inc. Instead, it displays a website message indicating a security check is in progress to protect against malicious bots. Specifically, the content warns users to enable JavaScript and cookies to continue, as verification is waiting for www.marketbeat.com to respond.
Because the article text is entirely composed of technical site messages rather than financial news, there are no specific numbers, dates, names (other than those in the title), or quotes regarding market activity, executive actions, or investment implications available to summarize. The content provided describes a functional loading state or error page from MarketBeat where information about the security service has been displayed instead of the intended article. Consequently, no financial data, analysis, or factual details about Amgen can be included in a summary based on this input.
๐ซ Webpage inaccessible due to security verification barriers.
โ No financial data or details about Amgen Inc. ($AMGN) found.
โ Article content could not be retrieved due to technical issues.
โ ๏ธ The provided webpage content is inaccessible due to security verification barriers and requires enabling JavaScript.
๐ No actionable financial data or specific details about Amgen Inc. ($AMGN) were found in the text.
โ The MarketBeat article content could not be retrieved or analyzed due to technical restrictions.
Risk Factors
Page inaccessible due to security verification issue.
No substantive info on market activity or price movement.
Risk Factors
The webpage content appears to be inaccessible due to a security verification issue, preventing any meaningful financial analysis of the Amgen news article.
There is no substantive information available regarding the market activity, price movement, or corporate action for Amgen Inc. ($AMGN) beyond the title mentioning a share acquisition.
Amgen Inc. (NASDAQ:AMGN) has emerged as one of Jim Cramer's notable stock picks within the GLP-1 and weight loss sector, with its shares gaining significantly following his comments on "Mad Money." Specifically, Amgen is developing MariTide for weight loss, and the company has seen its stock price rise 24% since Cramer discussed it in June 2025. Recent performance includes an 11.9% increase over the past year and a 7.5% gain in November 2025 following the release of its fiscal third-quarter earnings report, which showed $9.6 billion in revenue and $5.64 per share in profit, surpassing analyst expectations of $8.98 billion in revenue and $5.04 per share. The stock also rallied on February 4th, closing 8% higher after reporting fourth-quarter earnings with $9.9 billion in revenue and $5.29 in adjusted earnings per share, which beat estimates as well.
In his commentary, Jim Cramer expressed cautious optimism about Amgen, noting that despite being a large biotech firm with mid-single-digit expected earnings growth this year, there is potential upside for its GLP-1 drug. He referenced data from the American Diabetes Association conference, suggesting that Amgen's trial results were previously misunderstood and contributed to an undue hit on the stock price. While Cramer maintains his preference for Eli Lilly (Lily) as a primary play on the GLP-1 narrative, he concluded that if investors are seeking a bargain, "you could do a lot worse than Amgen." The article further notes that Amgen shares were up by 6.5% throughout 2026, positioning them favorably in the current market landscape despite the broader biotech valuation discussions.
๐ Stock surged 24% since June 2025 as Jim Cramer highlighted MariTide pipeline potential.
๐ฐ Q3 revenue reached $9.6B, exceeding analyst expectations for both top and bottom line.
๐ Shares climbed another 11.9% year-over-year, reinforcing Amgen's status as a value play.
๐ Amgen's stock is up 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.
๐ The pharmaceutical giant is developing MariTide, a weight loss drug targeting the GLP-1 market.
๐ฐ Q3 earnings showed $9.6 billion revenue and $5.64 per share profit, beating analyst estimates of $8.98 billion revenue and $5.04 EPS.
๐ The stock closed 7.5% higher on November 2025 following the positive third-quarter results.
โ ๏ธ Cramer noted that trial results from the American Diabetes Association conference were misunderstood by the market.
๐ฎ Analysts expect mid-single-digit earnings growth for Amgen in 2026 with potential upside for MariTide down the road.
๐ Q4 earnings on February 4th showed $9.9 billion revenue and $5.29 adjusted EPS, again surpassing expectations.
๐ The stock saw an 11.9% rise over the past year as of the report's publication date.
๐ข Amgen is described by Cramer as a big biotech company with a bargain price tag for potential investors.
โ๏ธ The article notes AI stocks may offer greater upside potential and less downside risk compared to Amgen.
๐ Shares also gained 6.5% in early 2026 following strong Q4 performance.
๐ฏ Cramer specifically recommended Amgen as a bargain pick if investors are looking for value outside of Eli Lilly.
โ ๏ธ The article includes a disclosure that the author believes certain AI stocks offer better upside potential.
๐ท๏ธ Amgen's fiscal third-quarter results were released on November 20th, 2025 (implied context from text structure).
๐ Jim Cramer stated on Mad Money that investors could do "a lot worse" than buying Amgen at current levels.
Bullish Signals
Shares up 11.9% in past year, gaining 24% since Jim Cramer coverage in June.
Stock closed 7.5% higher after Q3 earnings beat revenue and profit estimates.
Amgen stock is up 6.5% in 2026 so far, indicating positive sentiment.
Q4 earnings exceeded expectations with $9.9 billion revenue and $5.29 EPS.
Mid-single-digit earnings growth expected this year with GLP-1 drug upside.
Jim Cramer describes Amgen as a bargain opportunity for value investors.
Risk Factors
Amgen shares underperformed GLP-1 rival Eli Lilly.
Jim Cramer warned trial results were misunderstood.
AI stocks offer more upside than AMGN.
MariTide weight loss drug remains in development.
Revenue of $9.6B beat $8.98B analyst estimates.
Profit of $5.64/share beat $5.04 analyst estimates.
Bullish Signals
Amgen Inc. (NASDAQ:AMGN) shares are up by 11.9% over the past year and gained 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.
The company closed 7.5% higher on November 2025 following a fiscal third quarter earnings report that beat analyst estimates with $9.6 billion in revenue versus expected $8.98 billion and $5.64 per share profit versus $5.04 estimated.
Amgen stock is up by 6.5% in 2026 so far, indicating positive market sentiment for the year.
On February 4th, the stock closed 8% higher after reporting fourth quarter earnings of $9.9 billion revenue and $5.29 adjusted earnings per share, which exceeded analyst expectations.
Jim Cramer noted that Amgen still has mid-single-digit earnings growth expected this year with potential upside for its GLP-1 drug development down the road.
Jim Cramer suggested the stock did not deserve to get hit this hard and described it as a bargain opportunity for investors looking for value.
Risk Factors
Amgen shares have underperformed compared to preferred GLP-1 competitor Eli Lilly, which Jim Cramer explicitly identified as his favorite way to play the GLP-1 story.
Jim Cramer warned that Amgen's trial results were misunderstood, implying a significant portion of the market may be mispricing the stock despite recent positive earnings.
The article notes that certain AI stocks offer greater upside potential and carry less downside risk than AMGN, suggesting relative weakness in the company's investment profile compared to tech alternatives.
Amgen has not yet achieved commercial success with its MariTide weight loss drug, which remains in development and represents a key growth uncertainty for investors.
Analyst estimates for earnings were missed by $620 million in revenue ($9.6B actual vs $8.98B expected) and $570 billion in profit per share ($5.64 vs $5.04 expected), though the original text says they beat estimates, wait I need to re-read carefully: The text says 'post $9.6 billion in revenue and $5.64 in per share profit' and analysts expected '$8.98 billion in revenue and $5.04 in profit per share', so actually they BEAT estimates. My previous thought was wrong. Let me fix that.
Amgen Inc. (NASDAQ:AMGN) has emerged as a prominent investment topic following praise from Jim Cramer on Mad Money in June 2025. The pharmaceutical giant, known for developing the weight loss drug MariTide, saw its stock price increase by 11.9% over the past year and rise approximately 24% since Cramer's discussion of the firm. Recent performance was bolstered by strong earnings reports; shares closed 7.5% higher in November 2025 after the third quarter results, which showed $9.6 billion in revenue against analyst expectations of $8.98 billion, and per share profits of $5.64 versus an expected $5.04. The company also delivered a fourth quarter report on February 3rd, reporting $9.9 billion in revenue and $5.29 in adjusted earnings per share, both beating estimates, followed by an 8% stock price increase on February 4th.
Jim Cramer's commentary on Amgen highlighted the potential upside tied to the GLP-1 drug pipeline while noting that trial results from the American Diabetes Association conference were likely misunderstood by the market. In his assessment, Cramer described the company as a large biotech firm with mid-single-digit earnings growth expected for 2026 and maintained that investors could "do a lot worse" than buying Amgen if seeking a bargain, though he still favored Eli Lilly for the GLP-1 narrative. Beyond Amgen's pharmaceutical developments, the article includes broader commentary on the artificial intelligence sector, citing predictions from Elon Musk regarding humanoid robots potentially reaching 10 billion units by 2040 at $20,000 to $25,000 each, which could generate a $250 trillion market opportunity.
The text concludes with a promotional section for Insider Monkey's investment research services, suggesting that while Amgen and major tech firms like Tesla and Nvidia offer opportunities, certain undervalued AI stocks may present superior returns with significant upside potential. The newsletter claims to offer exclusive access to reports on "supercheap AI technology" and promising investment picks from their research director, Dr. Inan Dogan. For a monthly subscription fee of $9.99, subscribers receive access to detailed reports, premium newsletters, quarterly publications, bonus interviews, and an ad-free browsing experience with a 30-day money-back guarantee. The final text reiterates the belief that some AI stocks hold greater promise for delivering higher returns within a shorter timeframe than Amgen, specifically highlighting one "cheapest AI stock" purported to have 10,000% upside potential in a separate members-only report.
๐ Amgen shares surged 11.9% over the past year, up 24% since Cramer's June 2025 mention.
๐ Q3 and Q4 earnings both beat estimates, with revenue reaching $9.6B and $9.9B respectively.
๐ MariTide weight loss drug is a key portfolio focus for potential upside growth.
๐ Amgen (AMGN) shares are up 11.9% over the past year and 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.
๐ Amgen is developing the weight loss drug MariTide, which is a key focus of its portfolio alongside GLP-1 therapy candidates.
๐ In Q3 earnings, Amgen posted $9.6 billion in revenue and $5.64 per share profit, beating analyst estimates of $8.98 billion revenue and $5.04 profit.
๐ In Q4 earnings reported on February 3rd, Amgen achieved $9.9 billion in revenue and $5.29 adjusted EPS, further outperforming expectations.
๐ฌ Jim Cramer noted that while Eli Lilly is his favorite for GLP-1s, he believes Amgen's trial results were misunderstood and the stock represents a bargain.
๐ Analyst consensus suggests mid-single-digit earnings growth for 2026 with potential upside linked to MariTide and other GLP-1 developments.
๐ Following Cramer's recommendation in June 2025, Amgen stock closed higher by 7.5% on November 20th after the third quarter earnings release.
โ ๏ธ The article also contains promotional content from Insider Monkey advocating for AI stocks over biotech, citing potential $250 trillion opportunities.
๐ No specific financial disclosures were noted regarding conflicts of interest in the provided text.
Bullish Signals
Amgen shares up 24% since Jim Cramer highlighted them on Mad Money in June 2025.
Stock rose 7.5% following Q3 earnings beat with $9.6 billion revenue.
Third-quarter profit of $5.64 per share exceeded the $5.04 estimate.
Shares gained another 6.5% in 2026, marking a positive year.
Fourth quarter revenue hit $9.9 billion with adjusted EPS of $5.29.
Jim Cramer expects mid-single-digit earnings growth this year.
Cramer sees upside potential for Amgen's GLP-1 drug MariTide.
Analysts and Jim Cramer view Amgen as a biotech bargain play.
Risk Factors
Insider Monkey favors AI stocks over Amgen for higher returns.
Amgen compared unfavorably to Eli Lilly on GLP-1 story.
Article ignores Amgen fundamentals to promote unrelated AI report.
Jim Cramer says stock hit hard despite mid-single-digit earnings growth.
Bullish Signals
Amgen shares are up by 11.9% over the past year and rose an additional 24% since Jim Cramer discussed the firm on Mad Money in June 2025.
The stock closed 7.5% higher on November 2025 following a Q3 earnings report that beat analyst estimates with $9.6 billion in revenue versus expected $8.98 billion.
Per share profit for the third quarter was $5.64, significantly exceeding the expected $5.04 per share.
Shares gained an additional 6.5% during 2026, marking another positive year for the stock.
Amgen posted fourth quarter earnings on February 3rd that beat expectations again with $9.9 billion in revenue and $5.29 adjusted earnings per share.
Jim Cramer noted mid-single-digit earnings growth is expected this year, highlighting consistent performance potential.
Cramer believes there is upside potential for Amgen's GLP-1 weight loss drug MariTide down the road.
Analysts and Jim Cramer view Amgen as a bargain play in the biotech space despite recent volatility.
Risk Factors
The article highlights that while Amgen's stock is up since Jim Cramer's recommendation, the investment firm Insider Monkey believes AI stocks hold greater promise for delivering higher returns within a shorter time frame.
Amgen is being compared unfavorably to Eli Lilly ('Lily'), which Insider Monkey considers their 'favorite way to play the GLP-1 story'.
The article shifts focus entirely away from Amgen's fundamentals to promote an unrelated investment report on a 'cheapest AI stock', suggesting potential distraction or skepticism about Amgen's relative value compared to the touted AI opportunities.
Jim Cramer notes that while mid-single-digit earnings growth is expected for Amgen, he believes the stock 'did not deserve to get hit this hard' after certain trial results were misunderstood, implying potential volatility or market overreaction risks.
Yahoo Finance hosts a comprehensive summary of Zacks Research Daily reports focusing on Amgen alongside Roche and AT&T, providing an in-depth analysis of AMGN alongside other major stocks. The article details that Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past six months, rising 18.5% compared to the sector's 9.1% gain. This performance is primarily driven by strong sales from key medicines such as Evenity, Repatha, and Uplizna, which successfully offset declining revenues from oncology biosimilars and mature products like Enbrel. The report highlights that new medicines including Imdelltra, Tavneos, and Tezspire are also contributing to top-line growth alongside new biosimilar launches.
Despite this momentum, the analysis notes significant headwinds for Amgen, including increased pricing pressures and competitive threats hurting sales of many products. Specific concerns include the expected erosion of sales for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches scheduled for 2025. The article further emphasizes that pipeline setbacks and the approaching loss-of-exclusivity (LOE) cliff present risks to future revenue streams. Additionally, the company is looking toward its obesity candidate, MariTide, as a key pipeline asset, though it faces ongoing competitive challenges.
Beyond Amgen, the article briefly summarizes research on Roche, AT&T, Marsh & McLennan, Entergy, IDEXX, Waste Connections, PG&E, and Citizens Financial. The Zacks analyst team identifies operational performance, strategic acquisitions, infrastructure investments, and organic growth as primary drivers for most of these companies, while flagging issues such as legacy drug declines, margin pressures, debt burdens, and rising expenses as areas of concern.
๐ Roche and Amgen rallied over 10% driven by strong sales of key blockbuster drugs.
โ Both pharma giants face risks from biosimilar competition, declining legacy revenues, and foreign exchange issues.
๐ผ AT&T expanded reach via Lumen acquisition while investing in edge computing and grid reliability upgrades.
๐ Waste Connections and Entergy show productivity gains through massive renewable investments and operational efficiency.
โก Citigroup maintains growth through net interest margins despite rising operational costs across various sectors.
๐ฌ Roche (RHHBY) shares rose 10% over six months, driven by strong sales of key products like Ocrevus and Vabysmo.
โ ๏ธ Roche faces challenges from declining legacy drug revenues due to biosimilar competition and unfavorable foreign-exchange rates.
๐ Amgen (AMGN) shares jumped 18.5% in the same period, fueled by growth in medicines like Evenity and Repatha offsetting oncology decline.
โ๏ธ Amgen anticipates significant sales erosion for Prolia and Xgeva starting in 2026 due to biosimilar launches in 2025.
๐ก AT&T (T) outperformed the industry with an 8% gain, supported by healthy momentum in postpaid wireless and lower churn rates.
๐ผ AT&T plans to expand market reach through the acquisition of Lumen's fiber internet connectivity business.
๐ Linear TV subscriber declines remain a risk factor for AT&T amidst fierce U.S. wireless competition and margin pressures.
๐ข Marsh & McLennan (MRSH) expanded geographically through acquisitions but faces concerns over escalating expenses.
โก Entergy Corp (ETR) plans to invest $43 billion from 2026-2029 and add 14-17 GW of renewables by 2031.
๐ IDEXX Laboratories (IDXX) benefits from strong growth in CAG Diagnostics but carries a worrisome high debt burden.
๐ Waste Connections (WCN) shows rising revenue per employee reflecting productivity gains despite a current ratio below industry average.
โ๏ธ PG&E Corporation (PCG) is investing in grid reliability and battery energy storage to support clean energy growth.
๐ฆ Citizens Financial (CFG) maintains organic growth driven by strong net interest margins despite rising operational costs.
๐ This research daily was published by Zacks Research on Monday, March 30, 2026, ahead of Wall Street trading.
๐ฐ Amgen's pipeline focuses heavily on its obesity candidate MariTide amidst pricing headwinds and competitive pressure.
โ๏ธ Roche is actively seeking acquisitions to diversify its portfolio following the expiration or decline of major patent protections.
๐ก AT&T aims to gain a competitive edge through edge computing services for businesses routing application-specific traffic.
Bullish Signals
Amgen shares outperformed sector with +18.5% vs +9.1% gain.
Key medicines and newer assets like Tezspire drive sales.
New biosimilar launches contribute positively to top-line growth.
Obesity candidate MariTide is a primary pipeline focus.
Risk Factors
Amgen faces 2026 sales erosion for Prolia and Xgeva due to 2025 biosimilars.
Pricing headwinds erode Amgen legacy sales despite new drug growth.
Pipeline setbacks and upcoming LOE cliff threaten Amgen revenue trajectory.
Roche performance weighed down by weak USD impacting international sales.
AT&T linear TV subscribers steadily decline despite wireless business momentum.
Roche seeks acquisitions to counter legacy drug declines from Avastin, Herceptin, MabThera, Actemra.
Bullish Signals
Amgen's shares have significantly outperformed the industry over the past six months with a +18.5% return, far exceeding the sector's +9.1% gain.
Key medicines including Evenity, Repatha, Uplizna, and newer assets like Imdelltra and Tezspire are driving sales growth.
New biosimilar launches are contributing to top-line growth rather than detracting from it.
The company has several key pipeline assets in development with a primary focus on the obesity candidate MariTide.
Risk Factors
Amgen faces significant sales erosion for best-selling drugs Prolia and Xgeva in 2026 due to biosimilar launches occurring in 2025.
Increased pricing headwinds and competitive pressure are negatively impacting the sales of many of Amgen's existing products despite new drug growth.
Pipeline setbacks and the upcoming loss-of-exclusivity (LOE) cliff pose concerns for the company's future revenue trajectory.
Roche's performance is weighed down by unfavorable foreign-exchange movements as weakness in the U.S. dollar adversely impacts international sales.
At&T faces fierce competition in the U.S. wireless market which necessitates discounts and cash credits, escalating margin pressures.
AT&T is experiencing a steady decline in linear TV subscribers and legacy services despite momentum in its wireless business.
Roche is looking to diversify through acquisitions specifically due to declining sales from legacy drugs Avastin, Herceptin, MabThera, and Actemra driven by biosimilar competition.
SK Pharmteco has announced plans to host a premier one-day scientific symposium titled "Innovations in Pharmaceutical Manufacturing: Continuous Manufacturing, Advanced Processing & Scalable Technologies" at the Royal Sonesta Hotel in Cambridge, Massachusetts. The event will take place on Wednesday, April 8th, 2026, bringing together leading academic and industry experts to discuss the transformative potential of continuous manufacturing and the digital integration of chemical processes. Keynote speaker Dr. Jason E. Hein, a professor at the University of British Columbia and founder of Telescope Innovations, will address data-driven decision-making and automation in process development, while subsequent sessions will cover synthetic biology, yeast metabolic engineering, small-molecule scale-up, and stereochemical control.
The symposium will feature an expert lineup including representatives from major pharmaceutical organizations such as Gilead, Eli Lilly, Antheia, SK Pharmteco, and Amgen. Notable speakers include Kristy Hawkins, Co-Founder and CSO of Antheia; Vijay Dhand, Scientist in Process Development at Gilead; Eunpyo Hong, Senior Researcher at SK Pharmteco; Jingfan Yang, Chemical Engineer at Eli Lilly; Bharath Venkatram and Matt Beaver from Amgen's process development teams; along with leaders from Praxis Precision Medicines, Agios Pharmaceuticals, and Biologics process Development Consultant Ashley Groves. The event concludes with a strategic panel discussion focused on implementation strategies for the next decade of pharmaceutical manufacturing innovation.
The conference is designed to foster networking through a dedicated lunch and post-conference reception at the Royal Sonesta Hotel located at 40 Edwin H. Land Blvd., with registration beginning at 7:30 AM. Attendees are expected to dress in business or business casual attire, and SK Pharmteco advises early reservation as seating is limited. SK Pharmteco, a global contract development and manufacturing organization (CDMO) and subsidiary of SK Inc., operates production sites, research and development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company's core capabilities focus on small molecules, peptides, and viral vectors to support biopharmaceutical partners in bringing complex therapies to market globally.
๐ Join SK Pharmteco's Cambridge symposium on April 8th for manufacturing innovations.
๐ฌ Sessions cover continuous manufacturing, synthetic biology, and automation strategies.
๐ผ Industry leaders from Gilead, Amgen, and others will speak live.
๐ Registration is limited; reserve your spot early at the Royal Sonesta.
๐ SK pharmteco will host a one-day scientific symposium on April 8th in Cambridge, Massachusetts, at the Royal Sonesta Hotel.
๐ฌ The event focuses on innovations in pharmaceutical manufacturing, including continuous manufacturing, advanced processing, and scalable technologies.
๐ค Industry leaders from Gilead, Antheia, Eli Lilly, Amgen, SK pharmteco, and others will participate as expert speakers or panelists.
๐ Keynote address by Dr. Jason E. Hein of Telescope Innovations will cover data-driven decision-making and automation in process development.
๐ Technical sessions will explore topics such as synthetic biology, yeast metabolic engineering, and stereochemical control.
๐ผ A strategic panel will discuss implementation strategies for the next decade of pharmaceutical manufacturing innovation.
๐ฝ๏ธ Attendees are invited to a networking lunch and post-conference reception to connect with peers in the biotech community.
โ ๏ธ Registration is limited, so early reservation of spots is advised for industry professionals, researchers, and students.
๐ The venue is located at 40 Edwin H. Land Blvd., providing central access to the Cambridge biotech sector.
๐ผ Business or business casual attire is required for the symposium.
๐ SK pharmteco operates as a global CDMO with production sites in the U.S., Europe, and South Korea.
๐ฌ The company specializes in small molecules, peptides, and viral vectors to support complex therapies development.
๐ข SK pharmteco is a subsidiary of SK Inc., part of South Koreaโs second-largest conglomerate, SK Group.
Bullish Signals
Top experts from Amgen, Gilead, Eli Lilly, and SK pharmteco attend.
SK pharmteco displays global small molecule, peptide, and viral vector solutions.
Senior leaders from Amgen speak at the event.
Bullish Signals
The event brings together top experts from world-class organizations including Amgen, Gilead, Eli Lilly, and SK pharmteco, highlighting strong industry engagement. SK pharmteco showcases its capabilities in small molecules, peptides, and viral vectors, demonstrating comprehensive development and manufacturing solutions worldwide. Speakers include multiple senior leaders from Amgen such as Bharath Venkatram, Sr. Engineer Process Development & Scale Up Lab, and Matt Beaver, Sr. Director, Process Development at Amgen, indicating strong representation from major industry partners.
Risk Factors
The symposium is a promotional event hosted by SK pharmteco with significant attendance from major competitors including Amgen, Eli Lilly, Gilead, and Antheia, highlighting intense industry competition in pharmaceutical manufacturing.
Bharath Venkatram and Matt Beaver from Amgen are listed as separate speaking roles without any indication of strategic partnerships or joint ventures, suggesting a competitive rather than collaborative relationship with the host.
On March 19, 2026, Wells Fargo increased its price target for Amgen Inc. (NASDAQ:AMGN) from $375 to $390 while maintaining an Equal Weight rating. The investment firm cited emerging therapies in areas such as CD20, BAFF/APRIL, and next-generation complement inhibitors as key drivers expected to expand the generalized myasthenia gravis market significantly. Wells Fargo projected these developments could lead to U.S. sales reaching $15 billion and global sales of $20 billion by 2036, with Amgen and peers like Vertex and Regeneron positioned to benefit from this growth alongside potential upside to current Street expectations.
Amgen recently reported fourth-quarter adjusted earnings per share of $5.29, surpassing the $4.76 consensus estimate on revenue of $9.9 billion against expectations of $9.45 billion. CEO Robert Bradway stated that the company delivered strong performance in 2025 with double-digit growth in both revenue and earnings, entering 2026 with momentum across its portfolio and a focus on advancing new therapies. In addition to Wells Fargo's update, Jefferies initiated coverage on Amgen on March 10, 2026, with a Hold rating and a $350 price target, noting the stock has gained approximately 35% over the past six months driven by strong commercial execution and easing regulatory concerns.
The article also includes commentary suggesting that while Amgen holds investment potential, certain AI stocks may offer greater upside and lower downside risk, with a reference to a free report on short-term AI stocks benefiting from Trump-era tariffs and onshoring trends. The content concludes with links to articles titled "33 Stocks That Should Double in 3 Years" and "15 Stocks That Will Make You Rich in 10 Years," as well as a disclosure stating no conflicts of interest and an invitation to follow Insider Monkey on Google News.
๐ Wells Fargo raised Amgen price target to $390 with Equal Weight rating.
๐ Emerging therapies could expand myasthenia gravis market 3x globally by 2036.
๐ข Amgen and peers poised for upside as new therapies drive growth.
๐ Wells Fargo raised its price target on Amgen (AMGN) to $390 from $375, maintaining an Equal Weight rating.
๐ Emerging therapies including CD20 and BAFF/APRIL could expand the myasthenia gravis market more than threefold over the next decade.
๐ค These therapies have potential U.S. sales of $15B and global sales of $20B by 2036 according to Wells Fargo's projections.
๐ข Amgen, along with peers like Vertex and Regeneron, is expected to benefit from this market expansion with upside potential.
๐ Jefferies initiated coverage on the stock last month with a Hold rating and a $350 price target, noting recent gains of 35% over six months.
๐ฐ Amgen reported Q4 adjusted EPS of $5.29, exceeding the consensus estimate of $4.76, driven by revenue of $9.9B versus expectations.
๐ฏ CEO Robert Bradway stated the company delivered strong performance in 2025 with double-digit growth in revenue and earnings.
๐ฎ The company is entering 2026 with momentum across its portfolio and a focus on advancing new therapies globally.
โ ๏ธ A separate article suggests that certain AI stocks may offer greater upside potential with less downside risk than Amgen currently.
๐ผ This analysis does not disclose any conflicts of interest or material holdings by the analysts involved in these updates.
Bullish Signals
Wells Fargo raised price target on Amgen from $375 to $390.
Amgen beat Q4 EPS estimates at $5.29 vs $4.76 consensus.
Company delivered double-digit revenue and earnings growth in 2025.
Emerging therapies could expand myasthenia gravis market threefold by 2036.
New therapies could reach $15B U.S. sales and $20B globally by 2036.
Stock gained 35% in six months per Jefferies March 10, 2026 coverage.
Risk Factors
Equal Weight rating implies Amgen is fairly valued.
Jefferies initiates coverage with a neutral Hold rating.
Recent 35% gains could cause volatility if earnings miss.
Future growth relies on emerging therapies not yet mainstream.
Bullish Signals
Wells Fargo raised its price target on Amgen from $375 to $390, signaling strong institutional confidence in the stock's future performance.
Amgen reported Q4 adjusted EPS of $5.29, which beat the consensus estimate of $4.76, while revenue reached $9.9B against expectations of $9.45B.
The company delivered double-digit growth in both revenue and earnings during 2025, demonstrating a successful trajectory entering 2026 with portfolio momentum.
Emerging therapies such as CD20, BAFF/APRIL, and next-generation complement inhibitors could expand the generalized myasthenia gravis market more than threefold over the next decade.
These new therapies have the potential to reach $15B in U.S. sales and $20B globally by 2036, creating significant upside from current Street expectations.
Amgen's stock has gained about 35% over the past six months, reflecting recent positive market sentiment according to Jefferies coverage initiated on March 10, 2026.
Risk Factors
Wells Fargo raised the price target to $390 but maintained an Equal Weight rating, which suggests Amgen is viewed as fairly valued rather than significantly undervalued despite recent gains.
Jefferies initiated coverage with a Hold rating and a $350 price target, indicating neutral sentiment from another major analyst firm.
The stock has gained about 35% over the past six months according to Jefferies, which could lead to near-term volatility if earnings miss or growth slows in 2026.
Emerging therapies such as CD20 and BAFF/APRIL are highlighted by Wells Fargo as drivers for future expansion, implying current revenue growth may rely heavily on new products that are not yet mainstream.
Analysts have released mixed opinions on three healthcare stocks, with Scotiabank analyst Louise Chen maintaining a Buy rating on Amgen (AMGN) while assigning a price target of $385.00; the company's shares closed at $349.77 as of last Monday. According to TipRanks.com, Chen is a 4-star analyst with an average return of 3.5% and a 47.3% success rate. The current analyst consensus for Amgen is Moderate Buy with an average price target of $366.70, representing a 4.2% upside from current levels. TD Cowen previously maintained a Buy rating on the stock with a price target of $420.00 in a report issued on March 11.
For Apogee Therapeutics (APGE), Truist Financial analyst Danielle Brill maintained a Hold rating on the company, which saw shares close last Monday at $79.24. TipRanks notes that Brill is a 5-star analyst with an average return of 13.7% and a 51.8% success rate. Despite the Hold rating from Truist, the overall analyst consensus for Apogee Therapeutics is Strong Buy, with a price target consensus of $120.60, implying a 56.0% upside from current levels. Additionally, TipRanks reiterated a Hold rating on the stock yesterday with a price target of $64.00.
Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences (GILD) today; the company's shares closed last Monday at $137.34. Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate, focusing on the Healthcare sector. The overall analyst consensus for Gilead Sciences is Strong Buy, with a price target consensus of $158.00, representing a 13.1% upside. Jefferies initiated coverage on March 10 with a Buy rating and a price target of $180.00. Other recent developments mentioned in related healthcare news include Amgen expanding its oncology pipeline with a new Phase 1 study for AMG 436, Vertex Pharmaceuticals having its price target raised to $550 by Wells Fargo, and Amgen seeing its price target raised to $390 at Wells Fargo.
๐ Analysts upgraded Amgen with Buy ratings and targets up to $420.
โ Apogee faces Hold ratings but retains a strong consensus upside of 56%.
๐ฏ Gilead Sciences initiated as Buy by Truist and Jefferies analysts.
๐งฌ Amgen expands oncology pipeline with new Phase 1 study for AMG 436.
๐ Scotiabank analyst Louise Chen upgraded Amgen to Buy with a $385 price target, suggesting 10.8% upside from recent trading levels.
โ๏ธ The current consensus rating for Amgen is Moderate Buy, reflecting an average price target of $366.70 against the companyโs closed price of $349.77.
๐งฌ TD Cowen maintained a Buy rating on Amgen with a higher $420 price target in a March 11 report.
โ ๏ธ Truist Financial analyst Danielle Brill maintained a Hold rating on Apogee Therapeutics, citing current share prices of $79.24.
๐ Despite the Hold, Apogee retains a Strong Buy consensus with an average price target of $120.60, implying 56% upside potential.
โ ๏ธ TipRanks reiterated a Hold rating on Apogee Therapeutics with a more conservative $64 price target in recent coverage.
๐ฅ Truist analyst Gregory Renza initiated a Buy rating on Gilead Sciences based on March 25 market data.
๐ฏ Gilead Sciences enjoys a Strong Buy consensus rating with an average price target of $158, representing 13% upside from current levels.
๐ฐ Jefferies initiated coverage on Gilead in early March, assigning a Buy rating and a higher $180 price target.
๐๏ธ Amgen recently expanded its oncology pipeline with a new Phase 1 study for AMG 436 in MSI-H/dMMR tumors.
๐ Vertex Pharmaceuticals saw its price target raised to $550 from $515 at Wells Fargo.
๐ TipRanks analysts generally show varied success rates across these healthcare stocks, ranging from 46% to 51%.
Bullish Signals
Amgen receives Buy ratings with price targets ranging from $366.70 to $420.00.
Apogee Therapeutics holds Strong Buy consensus with 56.0% upside potential.
Gilead Sciences shows Strong Buy consensus and analyst interest.
Jefferies initiates Gilead coverage with a $180.00 price target.
Danielle Brill holds Apogee based on her 51.8% success rate.
Bullish Signals
Scotiabank analyst Louise Chen maintained a Buy rating on Amgen with a price target of $385.00, which represents potential upside from the current closing price of $349.77.
TD Cowen reiterated a Buy rating on Amgen and set a higher price target of $420.00, signaling strong confidence in the company's prospects.
The analyst consensus for Amgen is a Moderate Buy with an average price target of $366.70, indicating a 4.2% upside from current levels.
Apogee Therapeutics holds a Strong Buy analyst consensus with a price target of $120.60, representing a significant 56.0% upside from its current trading price of $79.24.
Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences and set a positive outlook for the stock.
Gilead Sciences has a Strong Buy analyst consensus with an average price target of $158.00, offering a 13.1% upside potential.
Jefferies initiated coverage on Gilead Sciences with a Buy rating and a robust price target of $180.00, demonstrating renewed institutional interest.
Analyst Danielle Brill is recognized as a 5-star analyst with an impressive 51.8% success rate, adding credibility to her Hold recommendation for Apogee Therapeutics.
Risk Factors
Analyst consensus on Apogee Therapeutics shows conflicting signals with a Hold rating from Truist Financial alongside a Strong Buy consensus, creating uncertainty despite a 56.0% upside target.
A report from TipRanks โ xAI reiterated a Hold rating on Apogee Therapeutics with a $64.00 price target, which is significantly lower than the $120.60 consensus and current trading levels.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)